Clinical data
Other namesFKB01MD
Routes of
By mouth
Pharmacokinetic data
Elimination half-life4 hours[1]
Chemical and physical data
3D model (JSmol)
  • OCC1OC(C(O)C1O)C2(O)NC=CC(=O)N2
  • InChI=1S/C9H14N2O6/c12-3-4-6(14)7(15)8(17-4)9(16)10-2-1-5(13)11-9/h1-2,4,6-8,10,12,14-16H,3H2,(H,11,13)

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[2][1] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.[3]

See also


  1. ^ a b c "FKB01MD". Fabre-Kramer.
  2. ^ "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595. S2CID 16286323.
  3. ^ "TGBA01AD". AdisInsight. Springer Nature Switzerland AG.